Medicamen Biotech Limited (MEDICAMEQ) - Total Assets
Based on the latest financial reports, Medicamen Biotech Limited (MEDICAMEQ) holds total assets worth Rs3.67 Billion INR (≈ $39.70 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Medicamen Biotech Limited (MEDICAMEQ) net assets for net asset value and shareholders' equity analysis.
Medicamen Biotech Limited - Total Assets Trend (2006–2025)
This chart illustrates how Medicamen Biotech Limited's total assets have evolved over time, based on quarterly financial data.
Medicamen Biotech Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Medicamen Biotech Limited's total assets of Rs3.67 Billion consist of 55.4% current assets and 44.6% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 1.3% |
| Accounts Receivable | Rs689.00 Million | 23.2% |
| Inventory | Rs621.37 Million | 20.9% |
| Property, Plant & Equipment | Rs0.00 | 0.0% |
| Intangible Assets | Rs7.42 Million | 0.3% |
| Goodwill | Rs0.00 | 0.0% |
Asset Composition Trend (2006–2025)
This chart illustrates how Medicamen Biotech Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Medicamen Biotech Limited market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Medicamen Biotech Limited's current assets represent 55.4% of total assets in 2025, a decrease from 68.2% in 2006.
- Cash Position: Cash and equivalents constituted 1.3% of total assets in 2025, up from 0.4% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 23.2% of total assets.
Medicamen Biotech Limited Competitors by Total Assets
Key competitors of Medicamen Biotech Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.34 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥15.32 Billion |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
China | CN¥10.96 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
Medicamen Biotech Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.61 | 2.28 | 1.99 |
| Quick Ratio | 1.81 | 1.41 | 1.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rs1.38 Billion | Rs879.72 Million | Rs480.84 Million |
Medicamen Biotech Limited - Advanced Valuation Insights
This section examines the relationship between Medicamen Biotech Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.69 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 0.8% |
| Total Assets | Rs2.97 Billion |
| Market Capitalization | $37.33 Million USD |
Valuation Analysis
Below Book Valuation: The market values Medicamen Biotech Limited's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Medicamen Biotech Limited's assets grew by 0.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Medicamen Biotech Limited (2006–2025)
The table below shows the annual total assets of Medicamen Biotech Limited from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs2.97 Billion ≈ $32.11 Million |
+0.79% |
| 2024-03-31 | Rs2.95 Billion ≈ $31.85 Million |
+5.76% |
| 2023-03-31 | Rs2.79 Billion ≈ $30.12 Million |
+23.41% |
| 2022-03-31 | Rs2.26 Billion ≈ $24.41 Million |
+16.33% |
| 2021-03-31 | Rs1.94 Billion ≈ $20.98 Million |
+7.02% |
| 2020-03-31 | Rs1.81 Billion ≈ $19.61 Million |
+32.72% |
| 2019-03-31 | Rs1.37 Billion ≈ $14.77 Million |
+16.20% |
| 2018-03-31 | Rs1.18 Billion ≈ $12.71 Million |
+60.15% |
| 2017-03-31 | Rs734.01 Million ≈ $7.94 Million |
+22.30% |
| 2016-03-31 | Rs600.18 Million ≈ $6.49 Million |
-12.59% |
| 2015-03-31 | Rs686.63 Million ≈ $7.43 Million |
+6.32% |
| 2014-03-31 | Rs645.79 Million ≈ $6.98 Million |
-1.00% |
| 2013-03-31 | Rs652.34 Million ≈ $7.05 Million |
-5.33% |
| 2012-03-31 | Rs689.07 Million ≈ $7.45 Million |
-1.59% |
| 2011-03-31 | Rs700.18 Million ≈ $7.57 Million |
+21.38% |
| 2010-03-31 | Rs576.83 Million ≈ $6.24 Million |
+25.92% |
| 2009-03-31 | Rs458.11 Million ≈ $4.95 Million |
-11.51% |
| 2008-03-31 | Rs517.72 Million ≈ $5.60 Million |
+11.54% |
| 2007-03-31 | Rs464.17 Million ≈ $5.02 Million |
+37.25% |
| 2006-03-31 | Rs338.18 Million ≈ $3.66 Million |
-- |
About Medicamen Biotech Limited
Medicamen Biotech Limited, a pharmaceutical company, research, develops, manufactures, markets, sells, and distributes pharmaceutical formulations in India and internationally. The company offers drugs in various forms, including tablet, capsule, syrups, oral solution, and drops. Its products are used in therapeutic areas comprising cancer care, cardiology, CNS, diabetology, anti-infective, anti-… Read more